# MLN518 in Combination With Standard Induction Chemo. for Treatment of Patients With Newly Diagnosed Acute Myelogenous Leukemia

> **NCT00274248** · PHASE1 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.**

## Conditions studied

- Acute Myelogenous Leukemia

## Interventions

- **DRUG:** MLN518

## Key facts

- **NCT ID:** NCT00274248
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2007-05
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2008-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00274248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00274248, "MLN518 in Combination With Standard Induction Chemo. for Treatment of Patients With Newly Diagnosed Acute Myelogenous Leukemia". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00274248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*